Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy
Rugo H, Chow LWC, Cortes J, Fasching P, He XB, Hsu P, Huang CS, Kim SB, Lu YS, Melisko M, Nanda R, Pearce TE, Sharma P, Schwab R (2021)
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: AMER ASSOC CANCER RESEARCH
City/Town: PHILADELPHIA
Conference Proceedings Title: CANCER RESEARCH
DOI: 10.1158/1538-7445.sabcs20-ot-13-10
Authors with CRIS profile
Involved external institutions
OBI Pharma Inc
Taiwan (TW)
University of Kansas (KU)
United States (USA) (US)
National Taiwan University Hospital (NTUH) / 國立台灣大學醫學院附設醫院
Taiwan (TW)
OBI Pharma USA, Inc.
United States (USA) (US)
Chinese Academy of Medical Sciences (CAMS)
China (CN)
University of California, San Diego
United States (USA) (US)
University of California San Francisco (UCSF)
United States (USA) (US)
Asan Medical Center / 서울아산병원
Korea, Republic of (KR)
Hospital Universitario Ramón y Cajal
Spain (ES)
University of Chicago Medical Center
United States (USA) (US)
UNIMED Medical Institute
China (CN)
Taiwan (TW)
University of Kansas (KU)
United States (USA) (US)
National Taiwan University Hospital (NTUH) / 國立台灣大學醫學院附設醫院
Taiwan (TW)
OBI Pharma USA, Inc.
United States (USA) (US)
Chinese Academy of Medical Sciences (CAMS)
China (CN)
University of California, San Diego
United States (USA) (US)
University of California San Francisco (UCSF)
United States (USA) (US)
Asan Medical Center / 서울아산병원
Korea, Republic of (KR)
Hospital Universitario Ramón y Cajal
Spain (ES)
University of Chicago Medical Center
United States (USA) (US)
UNIMED Medical Institute
China (CN)
How to cite
APA:
Rugo, H., Chow, L.W.C., Cortes, J., Fasching, P., He, X.-B., Hsu, P.,... Schwab, R. (2021). Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy. In CANCER RESEARCH. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
MLA:
Rugo, Hope, et al. "Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy." Proceedings of the CANCER RESEARCH PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2021.
BibTeX: Download